Ellen Hertz

Dr. Ellen Hertz

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2024 in Nature Reviews Neurology
Verified
Journal Article
Closed access
PDF file
EHEllen Hertz
Ellen Hertz
YCYu Chen
Yu Chen
Ellen SidranskyEllen Sidransky
Ellen Sidransky

Verified
Journal Article
Open access
PDF file
MFMakaila Furderer
Makaila Furderer
EHEllen Hertz
Ellen Hertz
GLGrisel J. Lopez
Grisel J. Lopez
Ellen SidranskyEllen Sidransky
Ellen Sidransky
Deficient acid β-glucocerebrosidase activity due to biallelic mutations in GBA1 results in Gaucher disease (GD). Patients with this lysosomal storage disorder exhibit a wide range of associated manifestations, spanning from virtually asymptomatic adults to infants with severe neurodegeneration. While type 1 GD (GD1) is considered non-neuronopathic, a small subset of patients develop parkinsonian features. Variants in GBA1 are also an important risk factor for several common Lewy body disorders (LBDs). Neuropathological examinations of patients with GD, including those who developed LBDs, are rare. GD primarily affects macrophages, and perivascular infiltration of Gaucher macrophages is the most common neuropathologic finding. However, the frequency of these clusters and the affected anatomical region varies. GD affects astrocytes, and, in neuronopathic GD, neurons in cerebral cortical layers 3 and 5, layer 4b of the calcarine cortex, and hippocampal regions CA2–4. In addition, several reports describe selective degeneration of the cerebellar dentate nucleus in chronic neuronopathic GD. GD1 is characterized by astrogliosis without prominent neuronal loss. In GD-LBD, widespread Lewy body pathology is seen, often involving hippocampal regions CA2–4. Additional neuropathological examinations in GD are sorely needed to clarify disease-specific patterns and elucidate causative mechanisms relevant to GD, and potentially to more common neurodegenerative diseases.

25 July 2022 in Movement Disorders
Verified
Journal Article
Open access
DVDanielle Te Vruchte
Danielle Te Vruchte
ASAndrea Sturchio
Andrea Sturchio
DPDavid Priestman
David Priestman
PTPanagiota Tsitsi
Panagiota Tsitsi
EHEllen Hertz
Ellen Hertz
Per SvenningssonPer Svenningsson
Per Svenningsson
Background: Alteration in glycosphingolipids (GSLs) in Parkinson's disease (PD) still needs to be determined.Objectives: We evaluated if PD subjects show abnormal GSLs levels compared to healthy controls (HC) and if GSLs correlate with clinical features.Methods: We analyzed GSLs and glucosylceramide (GlcCer) in plasma using two normal‐phase high‐performance liquid chromatography assays; clinico‐demographic data were extracted.Results: Eighty PD subjects and 25 HCs were analyzed. Levels of GlcCer, GD1b, Gb4, GalNAcGA1, and b‐series were higher in PD patients than in HCs; total GSLs, GT1b, GM1a, GM3, GM2, and a‐series levels were lower in PD patients than in HCs. Changes in GSLs were present in PD subjects, with GlcCer levels similar to those in HCs. The results were similar after excluding certain GBA1 mutation carriers. Movement Disorder Society Unified Parkinson's Disease Rating Scale, Part III, correlated with Gb4 and Montreal Cognitive Assessment with GD1b levels.Conclusions: Multiple GSL abnormalities in plasma were detected in patients with and without GlcCer changes, indicating a broader shift in lipid homeostasis. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson Movement Disorder Society.

9 May 2025 in Communications Biology
Verified
Journal Article
Open access
PDF file
NTNahid Tayebi
Nahid Tayebi
JLJens Lichtenberg
Jens Lichtenberg
EHEllen Hertz
Ellen Hertz
Ellen SidranskyEllen Sidransky
Ellen Sidransky

30 September 2023 in Journal of Movement Disorders
Verified
Journal Article
Open access
PDF file
EHEllen Hertz
Ellen Hertz
GLGrisel Lopez
Grisel Lopez
JLJens Lichtenberg
Jens Lichtenberg
DHDietrich Haubenberger
Dietrich Haubenberger
NTNahid Tayebi
Nahid Tayebi
Ellen SidranskyEllen Sidransky
Ellen Sidransky
Biallelic mutations in GBA1 cause the lysosomal storage disorder Gaucher disease, and carriers of GBA1 variants have an increased risk of Parkinson’s disease (PD). It is still unknown whether GBA1 variants are also associated with other movement disorders. We present the case of a woman with type 1 Gaucher disease who developed acute dystonia and parkinsonism at 35 years of age during a recombinant enzyme infusion treatment. She developed severe dystonia in all extremities and a bilateral pill-rolling tremor that did not respond to levodopa treatment. Despite the abrupt onset of symptoms, neither Sanger nor whole genome sequencing revealed pathogenic variants in ATP1A3 associated with rapid-onset dystonia-parkinsonism (RDP). Further examination showed hyposmia and presynaptic dopaminergic deficits in [18F]-DOPA PET, which are commonly seen in PD but not in RDP. This case extends the spectrum of movement disorders reported in patients with GBA1 mutations, suggesting an intertwined phenotype.

26 October 2023 in medRxiv
Verified
Preprint
Open access
PDF file
NTNahid Tayebi
Nahid Tayebi
JLJens Lichtenberg
Jens Lichtenberg
EHEllen Hertz
Ellen Hertz
Ellen SidranskyEllen Sidransky
Ellen Sidransky
Biallelic mutations in GBA1 result in Gaucher disease (GD), the inherited deficiency of glucocerebrosidase. Variants in GBA1 are also a common genetic risk factor for Parkinson disease (PD). Currently, some PD centers screen for mutant GBA1 alleles to stratify patients who may ultimately benefit from GBA1 -targeted therapeutics. However, accurately detecting variants, especially recombinant alleles resulting from a crossover between GBA1 and its pseudogene, is challenging, impacting studies of both GD and GBA1 -associated parkinsonism. Recently, the software tool Gauchian was introduced to identify GBA1 variants from whole genome sequencing. We evaluated Gauchian in 90 Sanger-sequenced patients with GD and five GBA1 heterozygotes. While Gauchian genotyped most patients correctly, it missed some rare or de novo mutations due to its limited internal database and over-reliance on intergenic structural variants. This resulted in misreported homozygosity, incomplete genotypes, and undetected recombination events, limiting Gauchian’s utility in variant screening and precluding its use in diagnostics.